{"id":4516,"date":"2021-07-04T09:11:55","date_gmt":"2021-07-04T00:11:55","guid":{"rendered":"https:\/\/www.emukk.com\/WP\/?p=4510"},"modified":"2021-07-04T09:15:54","modified_gmt":"2021-07-04T00:15:54","slug":"losatran-ace2-inhibitor-did-not-show-any-therapeutic-effects-on-against-sars-cov-2-in-phase-ii-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.emukk.com\/WP\/en\/losatran-ace2-inhibitor-did-not-show-any-therapeutic-effects-on-against-sars-cov-2-in-phase-ii-clinical-trial\/","title":{"rendered":"losatran, ACE2 inhibitor, did not show any therapeutic effects on against SARS-CoV-2 in Phase II clinical trial\u00a0"},"content":{"rendered":"<p>A group from Department of Emergency Medicine, University of Minnesota, etc. has indicated that losatran, ACE2 inhibitor, did not show any therapeutic effects on against SARS-CoV-2.<br \/>\n<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8225661\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8225661\/<\/a><\/p>\n<p>This was a multicenter prospective double blind randomized placebo-controlled trial for the treatment of symptomatic outpatients with confirmed COVID-19 conducted across 3 hospital systems in Minnesota, United States between April and November 2020.<\/p>\n<p>The intervention was losartan 25 mg versus equally appearing placebo. Participants self-administered study drug orally twice daily for 10 days for participants with eGFR >60 mL\/min\/1.73 m2, and once daily for those with eGFR 30\u201360 mL\/min\/1.73 m2. The threshold for angiotensin receptor blockade is 20 mg daily, with twice daily dosing more effective than once daily due to a 6\u20139 h half-life of the active metabolite. This dose was chosen in lieu of a 50 mg twice daily (maximum) dose after the FDA raised safety concerns regarding the higher dose regimen. This dose is expected to provide 37% inhibition of the angiotensin receptor. <\/p>\n<p>The primary outcome did not differ significantly, and also viral loads were not statistically different between treatment groups at any time point.\u00a0This clinical trial was terminated.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A group from Department of Emergency Medicine, University of Minnesota, etc. has indicated that losatran, ACE2<\/p><\/div>\n<div class=\"blog-btn\"><a href=\"https:\/\/www.emukk.com\/WP\/en\/losatran-ace2-inhibitor-did-not-show-any-therapeutic-effects-on-against-sars-cov-2-in-phase-ii-clinical-trial\/\" class=\"home-blog-btn\">\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70,7],"tags":[],"class_list":["post-4516","post","type-post","status-publish","format-standard","hentry","category-nature-en","category-technology-en"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/4516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/comments?post=4516"}],"version-history":[{"count":2,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/4516\/revisions"}],"predecessor-version":[{"id":4518,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/4516\/revisions\/4518"}],"wp:attachment":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/media?parent=4516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/categories?post=4516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/tags?post=4516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}